DORIP1

Summary

DORIP1 (dopamine receptor interacting protein 1, HGNC:19834) is a protein-coding gene on chromosome 14q21.2, encoding Dopamine receptor-interacting protein 1 (Q4W4Y0). Could be a regulator of the dopamine receptor signaling pathway.

Predicted to act upstream of or within with a positive effect on NMDA selective glutamate receptor signaling pathway and cAMP-mediated signaling. Predicted to act upstream of or within several processes, including G protein-coupled dopamine receptor signaling pathway; memory; and neurogenesis.

Source: NCBI Gene 122525 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 16 total — 1 pathogenic
• MANE Select transcript: NM_001017923

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19834
Approved symbol	DORIP1
Name	dopamine receptor interacting protein 1
Location	14q21.2
Locus type	gene with protein product
Status	Approved
Aliases	DRIP-1, DRIP1
Ensembl gene	ENSG00000179476
Ensembl biotype	protein_coding
Entrez	122525

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000325192, ENST00000553841, ENST00000555826, ENST00000557112, ENST00000866782, ENST00000866783, ENST00000866784

RefSeq mRNA: 1 — MANE Select: NM_001017923 NM_001017923

CCDS: CCDS32069

Canonical transcript exons

ENST00000325192 — 5 exons

Exon	Start	End
ENSE00001228396	44905367	44907257
ENSE00001228402	44900435	44900959
ENSE00001491370	44897275	44897568
ENSE00003495940	44903207	44903296
ENSE00003501409	44904395	44904529

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 94.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4334 / max 144.9108, expressed in 1702 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139402	4.0316	1595
139403	2.4018	1201

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	94.30	gold quality
secondary oocyte	CL:0000655	91.30	gold quality
pancreatic ductal cell	CL:0002079	90.99	gold quality
buccal mucosa cell	CL:0002336	90.90	silver quality
epithelial cell of pancreas	CL:0000083	85.16	gold quality
cauda epididymis	UBERON:0004360	83.95	gold quality
caput epididymis	UBERON:0004358	83.11	gold quality
calcaneal tendon	UBERON:0003701	82.87	gold quality
myometrium	UBERON:0001296	82.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.64	gold quality
body of uterus	UBERON:0009853	82.36	gold quality
middle temporal gyrus	UBERON:0002771	82.29	gold quality
oocyte	CL:0000023	82.25	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.24	gold quality
popliteal artery	UBERON:0002250	81.94	gold quality
tibial artery	UBERON:0007610	81.93	gold quality
Brodmann (1909) area 23	UBERON:0013554	81.22	gold quality
corpus epididymis	UBERON:0004359	81.12	gold quality
aorta	UBERON:0000947	80.82	gold quality
endothelial cell	CL:0000115	80.64	gold quality
left coronary artery	UBERON:0001626	80.64	gold quality
mammary duct	UBERON:0001765	80.29	gold quality
epithelium of mammary gland	UBERON:0003244	80.24	gold quality
saphenous vein	UBERON:0007318	80.24	gold quality
lower esophagus muscularis layer	UBERON:0035833	80.19	gold quality
lower esophagus	UBERON:0013473	80.17	gold quality
coronary artery	UBERON:0001621	80.14	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	79.91	gold quality
upper arm skin	UBERON:0004263	79.82	gold quality
right coronary artery	UBERON:0001625	79.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

153 targeting DORIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784

Literature-anchored findings (GeneRIF, showing 1)

• our data suggest: (i) C14ORF28, GNB2L1, MLLT3, DRD2 and DARPP-32 are important in the pathogenesis of schizophrenia and bipolar disorder (PMID:20874815)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	DORIP1	ENSDARG00000102021
mus_musculus	Gm527	ENSMUSG00000047227
rattus_norvegicus	C6h14orf28	ENSRNOG00000023230

Protein

Protein identifiers

Dopamine receptor-interacting protein 1 — Q4W4Y0 (reviewed: Q4W4Y0)

All UniProt accessions (2): Q4W4Y0, G3V4G8

UniProt curated annotations — full annotation on UniProt →

Function. Could be a regulator of the dopamine receptor signaling pathway.

Subunit / interactions. Interacts with DRD1.

RefSeq proteins (1): NP_001017923* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR040029	C14orf28-like	Family

UniProt features (1 total): chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q4W4Y0-F1	83.15	0.33

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 134 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, ACTACCT_MIR196A_MIR196B, TGCACTT_MIR519C_MIR519B_MIR519A, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND, BASAKI_YBX1_TARGETS_DN, ACTTTAT_MIR1425P, CTTTGTA_MIR524, GOBP_G_PROTEIN_COUPLED_DOPAMINE_RECEPTOR_SIGNALING_PATHWAY, SENESE_HDAC3_TARGETS_DN, GOBP_GLUTAMATE_RECEPTOR_SIGNALING_PATHWAY, GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D, LIU_PROSTATE_CANCER_DN

GO Biological Process (6): G protein-coupled dopamine receptor signaling pathway (GO:0007212), memory (GO:0007613), gene expression (GO:0010467), obsolete cAMP-mediated signaling (GO:0019933), neurogenesis (GO:0022008), NMDA selective glutamate receptor signaling pathway (GO:0098989)

GO Molecular Function (0):

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synaptic transmission, dopaminergic	1
G protein-coupled receptor signaling pathway	1
cellular response to dopamine	1
learning or memory	1
macromolecule biosynthetic process	1
nervous system development	1
cell differentiation	1
NMDA glutamate receptor activity	1
ionotropic glutamate receptor signaling pathway	1

Protein interactions and networks

STRING

200 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DORIP1	KLHL28	Q9NXS3	642
DORIP1	DOCK10	Q96BY6	597
DORIP1	TOGARAM1	Q9Y4F4	446
DORIP1	PRPF39	Q86UA1	418
DORIP1	FIGNL2	A6NMB9	402
DORIP1	BSDC1	Q9NW68	390
DORIP1	ICE1	Q9Y2F5	371
DORIP1	EIF4H	Q15056	364
DORIP1	SFT2D1	Q8WV19	356
DORIP1	FKBP3	Q00688	349
DORIP1	DTNA	Q9Y4J8	345
DORIP1	ANKDD1A	Q495B1	324
DORIP1	SMIM28	A0A1B0GU29	305
DORIP1	PEX2	P28328	305
DORIP1	MTCL1	Q9Y4B5	265

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A1ZAW0, A8WS92, A8WZU5, B0JZ65, O60152, O62301, O94536, P16320, P24271, P34601, P34607, P87231, P90740, P91133, Q04149, Q04638, Q09884, Q16YA8, Q19546, Q196T9, Q1EHT7, Q21988, Q23243, Q23541, Q2KIN3, Q3SWY8, Q3T9Z9, Q45EK7, Q4KL13, Q4R4A2, Q4W4Y0, Q5EA92, Q5U2S3, Q6FYA6, Q6GM71, Q7M3K2, Q7YTB0, Q8N8R7, Q8WT44, Q91829

Diamond homologs: Q2KIN3, Q4KL13, Q4W4Y0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

16 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	5
Likely benign	1
Benign	6

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2426634	NC_000014.8:g.(?44820816)(45645917_?)del	Pathogenic

SpliceAI

876 predictions. Top by Δscore:

Variant	Effect	Δscore
14:44897564:GGGAG:G	donor_gain	1.0000
14:44897565:GGAGG:G	donor_gain	1.0000
14:44897566:G:T	donor_gain	1.0000
14:44903203:ATAGT:A	acceptor_loss	1.0000
14:44903204:TA:T	acceptor_loss	1.0000
14:44903205:A:AG	acceptor_gain	1.0000
14:44903206:G:GG	acceptor_gain	1.0000
14:44903206:GT:G	acceptor_gain	1.0000
14:44903206:GTC:G	acceptor_gain	1.0000
14:44903206:GTCC:G	acceptor_gain	1.0000
14:44903206:GTCCT:G	acceptor_gain	1.0000
14:44903294:TGG:T	donor_gain	1.0000
14:44903295:GG:G	donor_gain	1.0000
14:44903295:GGG:G	donor_gain	1.0000
14:44903296:GG:G	donor_gain	1.0000
14:44903297:G:GG	donor_gain	1.0000
14:44904388:A:AG	acceptor_gain	1.0000
14:44904389:TTTTA:T	acceptor_loss	1.0000
14:44904391:TTAG:T	acceptor_loss	1.0000
14:44904392:TAGGT:T	acceptor_loss	1.0000
14:44904393:A:AG	acceptor_gain	1.0000
14:44904393:AG:A	acceptor_gain	1.0000
14:44904393:AGGT:A	acceptor_gain	1.0000
14:44904394:G:GG	acceptor_gain	1.0000
14:44904394:GG:G	acceptor_gain	1.0000
14:44904394:GGT:G	acceptor_gain	1.0000
14:44904394:GGTG:G	acceptor_gain	1.0000
14:44904394:GGTGT:G	acceptor_gain	1.0000
14:44904491:GGC:G	donor_gain	1.0000
14:44904492:GC:G	donor_gain	1.0000

AlphaMissense

2054 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:44904454:T:A	V225D	0.993
14:44905425:T:C	F270L	0.993
14:44905427:C:A	F270L	0.993
14:44905427:C:G	F270L	0.993
14:44900757:T:A	W108R	0.992
14:44900757:T:C	W108R	0.992
14:44900863:T:C	L143P	0.992
14:44905443:T:A	W276R	0.992
14:44905443:T:C	W276R	0.992
14:44900850:T:C	F139L	0.990
14:44900852:T:A	F139L	0.990
14:44900852:T:G	F139L	0.990
14:44905426:T:C	F270S	0.990
14:44900619:T:C	F62L	0.989
14:44900621:C:A	F62L	0.989
14:44900621:C:G	F62L	0.989
14:44904460:T:C	L227S	0.988
14:44900829:T:C	F132L	0.987
14:44900831:T:A	F132L	0.987
14:44900831:T:G	F132L	0.987
14:44900913:T:C	C160R	0.986
14:44900900:T:G	C155W	0.985
14:44900614:A:T	D60V	0.984
14:44904429:T:C	F217L	0.984
14:44904431:C:A	F217L	0.984
14:44904431:C:G	F217L	0.984
14:44904451:T:C	F224S	0.984
14:44904474:T:A	W232R	0.984
14:44904474:T:C	W232R	0.984
14:44905383:G:C	A256P	0.984

dbSNP variants (sampled 300 via entrez): RS1000012068 (14:44898402 A>G), RS1000308755 (14:44904253 C>A,T), RS1000340555 (14:44906074 T>G), RS1000374803 (14:44905740 T>A), RS1000914335 (14:44902820 G>A,C), RS1001016554 (14:44897444 A>G), RS1001049279 (14:44897286 C>G,T), RS1001347005 (14:44902600 G>A), RS1001767926 (14:44907593 G>A,C,T), RS1001949645 (14:44901169 G>A), RS1002025464 (14:44896335 T>C), RS1002739667 (14:44906186 C>T), RS1003168578 (14:44898102 C>G,T), RS1003749839 (14:44904735 T>C,G), RS1003779412 (14:44904320 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:227650

GenCC curated gene-disease

Mondo (1): Fanconi anemia (MONDO:0019391)

Orphanet (1): Fanconi anemia (Orphanet:84)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004104_1	Body mass index (change over time) in lung cancer	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005937	longitudinal BMI measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005199	Fanconi Anemia	C15.378.050.085.080.280; C15.378.190.223.500.500.280; C16.320.077.280; C18.452.284.280

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	4
Valproic Acid	affects expression, decreases expression, increases expression	3
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	increases expression	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
butyraldehyde	decreases expression	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
GW 1929	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Copper	affects binding, increases expression	1
Demecolcine	increases expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Oxygen	increases expression	1
Potassium Chloride	decreases expression, decreases response to substance	1
Quercetin	decreases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

84 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06519786	PHASE3	UNKNOWN	Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia
NCT00000603	PHASE2	COMPLETED	Cord Blood Stem Cell Transplantation Study (COBLT)
NCT00001749	PHASE2	COMPLETED	Medical Treatment for Diamond Blackfan Anemia
NCT00004787	PHASE2	COMPLETED	Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
NCT00053989	PHASE2	COMPLETED	NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
NCT00084695	PHASE2	UNKNOWN	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
NCT00258427	PHASE2	COMPLETED	Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00453388	PHASE2	COMPLETED	Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia
NCT01071239	PHASE2	COMPLETED	Hematopoietic Stem Cell Transplant for Fanconi Anemia
NCT02143830	PHASE2	RECRUITING	HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
NCT02931071	PHASE2	COMPLETED	Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
NCT03206086	PHASE2	ACTIVE_NOT_RECRUITING	Eltrombopag for People With Fanconi Anemia
NCT03398824	PHASE2	COMPLETED	Pilot Study of Metformin for Patients With Fanconi Anemia
NCT03476330	PHASE2	COMPLETED	Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
NCT03579875	PHASE2	RECRUITING	Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03600909	PHASE2	TERMINATED	A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
NCT04232085	PHASE2	RECRUITING	Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT06045052	PHASE2	COMPLETED	Eltrombopag for Treatment of Fanconi Anemia
NCT00001399	PHASE1	COMPLETED	Gene Therapy for the Treatment of Fanconi’s Anemia Type C
NCT00005896	PHASE1	UNKNOWN	Phase I Pilot Study of CD34 Enriched, Fanconi’s Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi’s Anemia
NCT00006127	PHASE1	UNKNOWN	Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi’s Anemia
NCT00093743	PHASE1	COMPLETED	Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
NCT00243399	PHASE1	COMPLETED	Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
NCT00272857	PHASE1	COMPLETED	Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia
NCT00317876	PHASE1	COMPLETED	Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi’s Anemia
NCT00586274	PHASE1	TERMINATED	Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT01331018	PHASE1	TERMINATED	Gene Therapy for Fanconi Anemia
NCT01720147	PHASE1	COMPLETED	Quercetin in Children With Fanconi Anemia; a Pilot Study
NCT01917708	PHASE1	COMPLETED	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT00352976	PHASE2/PHASE3	COMPLETED	TBI Dose De-escalation for Fanconi Anemia
NCT01019876	PHASE2/PHASE3	COMPLETED	Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
NCT00005898	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi’s Anemia
NCT00167206	PHASE1/PHASE2	TERMINATED	Stem Cell Transplantation for Fanconi Anemia
NCT00305708	PHASE1/PHASE2	COMPLETED	Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
NCT00479115	PHASE1/PHASE2	COMPLETED	Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
NCT00590460	PHASE1/PHASE2	TERMINATED	Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
NCT00630253	PHASE1/PHASE2	COMPLETED	Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
NCT01001598	PHASE1/PHASE2	TERMINATED	Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
NCT02065869	PHASE1/PHASE2	TERMINATED	Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
NCT02678533	PHASE1/PHASE2	COMPLETED	Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor